1mg

Sector: Digital Health, E-Pharmacy and Diagnostics  |  HQ: Gurugram, Haryana, India  |  Founded: 2015  |  Employees: 4,000+

Listed as: Privately held  | 

Company overview

Tata 1mg is the digital health platform operated by 1MG Technologies Private Limited, an integrated e-pharmacy, online doctor consultation, and at-home diagnostics business. Originally founded in 2015 as a healthcare information portal, the platform pivoted to a transactional e-pharmacy in 2017 under co-founders Prashant Tandon, Gaurav Agarwal, and Vikas Chauhan. In June 2021 Tata Digital, the digital arm of Tata Sons, acquired a majority stake in 1MG and renamed the platform Tata 1mg as part of the broader Tata Neu super-app ecosystem. The platform offers prescription and over-the-counter medicines delivered through a network of fulfilment centres and last-mile partners across more than 1,000 cities, with hub operations in Gurugram, Mumbai, Bengaluru, and Chennai. It runs an in-house diagnostics business with NABL-accredited labs serving home sample collection in over 50 cities, an online doctor consultation network covering most specialties, and a curated wellness products marketplace. Tata 1mg sits alongside Netmeds (Reliance-owned), PharmEasy (API Holdings), Apollo 24|7, and Flipkart Health Plus as the principal organised e-pharmacy and digital health competitors in India. The platform serves both retail consumers and corporate health insurance partners through API-led pharmacy benefit management.

Financial performance and recent trajectory

Disclosed revenue (FY25): ₹1,950 crore (FY 2024-25 estimate).

Competitive position

Tata 1mg is among the top three e-pharmacies in India by GMV alongside PharmEasy and Apollo 24|7, with Netmeds and Flipkart Health Plus as the principal pursuers. Its competitive moats are the Tata Group brand and balance sheet, the integration with Tata Neu loyalty and payments, and the in-house diagnostics network that few competitors operate at comparable scale. Pricing in the segment is uniform around 20 to 25 percent discount to MRP, so customer acquisition cost, repeat rate, and the diagnostics attach rate are the differentiators. The principal headwinds are the protracted regulatory uncertainty around online sale of medicines under the Drugs and Cosmetics Act 1940 and the Drugs and Cosmetics Rules 1945, which the Ministry of Health has repeatedly proposed to amend with a specific e-pharmacy framework that has not yet been notified. Tata Digital holds over 70 percent equity stake and continues to fund operating losses as the platform builds market share.

Key risks

Regulatory uncertainty over the formalisation of e-pharmacy rules under the Drugs and Cosmetics Act Continued operating losses and capital absorption from Tata Digital Competitive intensity from PharmEasy, Apollo 24|7, Netmeds, and Flipkart Health

Outlook

Tata 1mg traces its origin to 2015 when the founding team pivoted Healthkartplus, a generic medicine price comparison tool, into a transactional e-pharmacy platform. The initial focus was chronic medication delivery for diabetes, cardiovascular, and oncology patients, segments where prescription refill cadence and household budget sensitivity made online ordering valuable. Series funding rounds from Sequoia Capital, Omidyar Network, Maverick Ventures, and HBM Healthcare Investments preceded the 2021 acquisition by Tata Digital for an enterprise value estimated at around USD 230 million for a 55 percent stake, with subsequent follow-on investments lifting Tata Digital ownership above 70 percent. The business is organised across four operating segments. The pharmacy segment, the largest by revenue, handles prescription and over-the-counter medicine fulfilment with the in-house drug catalogue and a network of third-party retail pharmacies onboarded through the partner programme. Order intake is principally through the Tata 1mg mobile app and website, with WhatsApp ordering as a secondary channel. The diagnostics segment operates phlebotomy collection across 50-plus cities feeding into a network of partner and owned NABL-accredited laboratories, with home collection turnaround targeted at 24 to 48 hours. The doctor consultation segment offers online consultations through a panel of empanelled doctors across general medicine, dermatology, gynaecology, paediatrics, and a range of specialities. The fourth segment is the digital health platform, including drug information, symptom checking, and corporate health benefits administration. The manufacturing footprint is light by design. Tata 1mg does not manufacture pharmaceuticals; it sources from authorised stockists and CFAs (carrying and forwarding agents) governed by drug distribution licences under the Drugs and Cosmetics Act. The principal fulfilment centres are at Gurugram (national hub), Mumbai (western region), Bengaluru (southern region), and Chennai, supplemented by smaller regional centres that handle short-radius dispensing. The diagnostics labs operate under separate ISO 15189 and NABL accreditation. Distribution is asset-light. Last-mile delivery uses a combination of in-house riders in core metros (typically same-day in tier-1 cities) and third-party logistics through Delhivery, Shadowfax, and Dunzo for tier-2 and tier-3 fulfilment. The order density in tier-1 metros supports sub-3-hour delivery economics, while tier-2 and tier-3 orders are typically next-day. Geographic coverage spans more than 1,000 cities with active SKU availability skewed toward chronic medication and wellness products. Financial trajectory is the most discussed dimension of Tata 1mg. Operating revenue grew from approximately ₹630 crore in FY22 to ₹1,170 crore in FY23, ₹1,650 crore in FY24, and an estimated ₹1,950 crore in FY25. Net loss has narrowed in percentage terms but remains material at an estimated ₹350 to ₹400 crore in FY25, driven by customer acquisition cost, fulfilment cost in tier-2 and tier-3, and diagnostics network build-out. Gross margin sits in the 20 to 25 percent band, with the diagnostics segment running materially higher gross margin than the pharmacy segment. Recent capex and corporate development activity has focused on diagnostics network expansion and integration with the Tata Neu super-app for loyalty and payments cross-pollination. Tata Digital has consolidated reporting of Tata 1mg, Tata Cliq, BigBasket, and Croma under the Tata Neu umbrella, and management commentary indicates a continued capex priority on supply chain automation at the four major fulfilment centres. Strategy through 2025 to 2030 is anchored on four pillars. First, scaling diagnostics to a meaningful share of revenue, targeting 25 to 30 percent of GMV mix versus an estimated 18 to 20 percent today. Second, deepening corporate health benefits partnerships with insurers and third-party administrators, where Tata 1mg can offer integrated pharmacy benefit management. Third, expanding tier-2 and tier-3 city coverage through partner pharmacy onboarding rather than direct fulfilment. Fourth, leveraging the Tata Neu cross-sell to reduce customer acquisition cost. The regulatory environment is the principal swing factor for the entire Indian e-pharmacy segment. The Drugs and Cosmetics Act 1940 and the Drugs and Cosmetics Rules 1945 do not specifically authorise online sale of medicines. The Ministry of Health and Family Welfare floated a draft e-pharmacy framework in 2018 and again in 2023, but neither has been notified. Multiple high court orders have pronounced on the legality of online pharmacy, with the Delhi High Court permitting operation subject to compliance with existing licensing. Tata 1mg, like its peers, operates under retail pharmacy licences issued under Rule 65 of the Drugs Rules and complies with prescription verification before dispensing scheduled drugs. The Companies Act 2013 governs corporate disclosure for 1MG Technologies Private Limited, and the Information Technology Rules 2021 apply to the platform layer. Risks are concentrated in four buckets. First, regulatory: a notification of the e-pharmacy rules could either formalise the market or impose onerous compliance requirements. Second, competitive: PharmEasy reset its pricing aggression after its IPO postponement, and Apollo 24|7 benefits from the parent pharmacy and hospital ecosystem. Third, unit economics: the customer acquisition cost in tier-1 metros has compressed but tier-2 and tier-3 customer acquisition cost remains elevated. Fourth, doctor consultation regulation under the Telemedicine Practice Guidelines 2020 issued by the National Medical Commission, which impose specific obligations on doctor verification, prescription generation, and record retention. Management quality is anchored by the founder team and the Tata Digital leadership, with Prashant Tandon continuing as CEO and Tata Digital nominees on the board. Tata Sons subsidiary Tata Digital reports indirectly into the Tata Sons consolidated audit and disclosure framework. Statutory audit is conducted by a Big Four firm. ESG positioning is moderate. The diagnostics business offers a legitimate public health benefit in the home sample collection segment, with last-mile pharmacy access reducing time and cost burden particularly for chronic care patients. Data privacy is a heightened concern given the volume of prescription and health record data; Tata 1mg complies with the Digital Personal Data Protection Act 2023 and the IT Rules 2021. Carbon footprint is light given the asset-light fulfilment model.

KAMRIT point of view

Building or competing with 1mg?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the digital health sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of 1mg and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use 1mg in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.